Author

R. V. Deev

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Organism:chicken / avian· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. A. Isaev· 1 shared A. A. Nedorubov· 1 shared A. K. Velichko· 1 shared A. M. Emelin· 1 shared A. N. Kazakova· 1 shared A. N. Turchin· 1 shared A. V. Ivanov· 1 shared A. V. Kashina· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. A. Isaev

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Unlocking DNA Damage Sensitivity of Cancer Cells: The Potential of Splicing Inhibitors

K. S. Anufrieva, M. M. Lukina, O. M. Ivanova, A. N. Kazakova, P. V. Shnaider, K. M. Klimina, V. A. Veselovsky, A. V. Luzhin, A. K. Velichko, O. L. Kantidze, E. N. Mochalova, M. P. Nikitin, A. V. Kashina, E. A. Vasilchikova, R. V. Deev, , V. O. Shender

This study shows splicing inhibitors induce DNA repair gene downregulation in cancer cells, creating a vulnerability that can be exploited by combining them with DNA-damaging agents.

bioRxiv · Oct 8, 2023 · PreprintCancer Biology

SARS-CoV-2 Subunit Virus-Like Vaccine Demonstrates High Safety Profile and Protective Efficacy: Preclinical Study

A. V. Vakhrusheva, A. V. Kudriavtsev, N. A. Kryuchkov, R. V. Deev, M. E. Frolova, K. A. Blagodatskikh, M. Djonovic, A. A. Nedorubov, E. Odintsova, A. V. Ivanov, E. A. Romanovskaya-Romanko, M. A. Stukova, A. A. Isaev, I. V. Krasilnikov

This paper evaluates a subunit vaccine, Betuvax-CoV-2, showing high safety and protective efficacy in preclinical models, leading to ongoing clinical trials.

bioRxiv · May 18, 2022 · PreprintPharmacology & Toxicology